UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.80-14, Article 80

2021

Volltextzugriff (PDF)

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study

Alzheimer's research & therapy, 2022-07, Vol.14 (1), p.1-105, Article 105

2022

Volltextzugriff (PDF)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2022-05, Vol.14 (1), p.70-70, Article 70

2022

Volltextzugriff (PDF)

CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609

Alzheimer's & dementia, 2013, Vol.8 (4), p.S743-S743

2013

Volltextzugriff (PDF)

Soluble BACE activity and sAPPβ levels do not differentiate Alzheimer's disease and age-matched control cerebrospinal fluid in the ADNI-1 cohort

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P201-P201

2013

Volltextzugriff (PDF)

Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P886-P886

2013

Volltextzugriff (PDF)

First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing

Alzheimer's & dementia, 2012-07, Vol.8 (4), p.P96-P96

2012

Volltextzugriff (PDF)

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

Alzheimer's research & therapy, 2016-04, Vol.8 (1), p.14, Article 14

2016

Volltextzugriff (PDF)

INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401-G000-201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P855-P855

2014

Volltextzugriff (PDF)

CONSIDERATION FOR “EARLY ALZHEIMER'S DISEASE (AD)” TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401-G000-201 TRIAL

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P778-P778

2014

Volltextzugriff (PDF)

A first-in-human study of BAN2401, a novel monoclonal antibody against beta-amyloid protofibrils

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P689-P689

2013

Volltextzugriff (PDF)

Pharmacology of BAN2401: A monoclonal antibody selective for beta-amyloid protofibrils

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P809-P809

2013

Volltextzugriff (PDF)

Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils: In vitro and ex vivo analyses

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P807-P808

2013

Volltextzugriff (PDF)

A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P808-P808

2013

Volltextzugriff (PDF)

Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program: Neuroimaging / evaluating treatments

Alzheimer's & dementia, 2020-12, Vol.16 (S4)

2020

Volltextzugriff (PDF)

Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status

Alzheimer's & dementia, 2020-01, Vol.16 (1), p.144-152

2020

Volltextzugriff (PDF)

P1‐041: APOE4 STATUS AND AMYLOID BURDEN DIFFERENCES ACROSS REGIONS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_4), p.P248-P248

2019

Volltextzugriff (PDF)

APOE4 STATUS AND AMYLOID BURDEN DIFFERENCES ACROSS REGIONS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P248-P248

2019

Volltextzugriff (PDF)

BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease (3006)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease

Journal of the neurological sciences, 2021-10, Vol.429, p.117847, Article 117847

2021

Volltextzugriff (PDF)

Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer’s disease

Alzheimer's & dementia, 2021-12, Vol.17 (S9), p.n/a

2021

Volltextzugriff (PDF)

From traditional biomarkers to transcriptome analysis in drug development

Current molecular medicine, 2005-02, Vol.5 (1), p.29-38

2005

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(88)
Dissertationen
(1)

Sprache

Englisch
(89)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Neurology
(14)
Alzheimer's Disease
(13)
Animals
(7)
Biological And Medical Sciences
(7)
Cerebrospinal Fluid
(7)
Female
(7)
Male
(7)
Biomarkers
(6)
Aged
(5)
Amyloid
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Middle Aged
(5)
Adult
(4)
Amino Acid Sequence
(4)
Base Sequence
(4)
Biomarkers - Cerebrospinal Fluid
(4)
Cell Biology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609

Soluble BACE activity and sAPPβ levels do not differentiate Alzheimer's disease and age-matched control cerebrospinal fluid in the ADNI-1 cohort

Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF

First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

INITIAL LEARNINGS FROM SCREENING STRATEGIES IN THE BAN 2401-G000-201 TRIAL: AN EARLY ALZHEIMER'S DISEASE STUDY

CONSIDERATION FOR “EARLY ALZHEIMER'S DISEASE (AD)” TRIALS WITH A SINGLE PRODROMAL AD AND MILD AD DEMENTIA POPULATION: ADNI DATA ANALYSIS AND INITIAL OBSERVATIONS FROM THE BAN2401-G000-201 TRIAL

A first-in-human study of BAN2401, a novel monoclonal antibody against beta-amyloid protofibrils

Pharmacology of BAN2401: A monoclonal antibody selective for beta-amyloid protofibrils

Microglial involvement and amyloid reduction with BAN2401/mAb158, a monoclonal antibody with high selectivity for protofibrils: In vitro and ex vivo analyses

A multimodal imaging study of mAb158, a murine monoclonal antibody with high selectivity for amyloid protofibrils, in Tg2576 mice

Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program: Neuroimaging / evaluating treatments

Amyloid burden assessed by three amyloid PET tracers in the elenbecestat MissionAD Phase 3 program

Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status

P1‐041: APOE4 STATUS AND AMYLOID BURDEN DIFFERENCES ACROSS REGIONS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM

APOE4 STATUS AND AMYLOID BURDEN DIFFERENCES ACROSS REGIONS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM

BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021)

Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease (3006)

Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease

Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330)

Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer’s disease

From traditional biomarkers to transcriptome analysis in drug development

Suchergebnisse filtern